Alto Neuroscience, Inc.

For the period ended Dec 31, 2025. Filed Mar 16, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 16, 2026

ANRO$27.80+10.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized.

		ALTO NEUROSCIENCE, INC.
Date:	March 16, 2026	By:	/s/ Amit Etkin
			Amit Etkin, M.D., Ph.D.President and Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons in the capacities and on the dates indicated:

Christopher Nixon Cox
Signature	Title	Date
/s/ Amit Etkin	President, Chief Executive Officer, and	March 16, 2026
Amit Etkin, M.D., Ph.D.	Chair of the Board of Directors
	(Principal Executive Officer)
/s/ Nicholas Smith	Chief Financial Officer and Chief Business Officer	March 16, 2026
Nicholas Smith	(Principal Financial Officer and Principal Accounting Officer)
/s/ Christopher Nixon Cox	Director	March 16, 2026
/s/ Andrew Dreyfus	Director	March 16, 2026
Andrew Dreyfus
/s/ Husseini Manji	Director	March 16, 2026
Husseini Manji, M.D.
/s/ Raymond Sanchez	Director	March 16, 2026
Raymond Sanchez, M.D.
/s/ Gwill York	Director	March 16, 2026
Gwill York

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.